Alemtuzumab in peripheral T-cell malignancies.
Dearden
Claire
C
The Royal Marsden Hospital, London, UK. Claire.Dearden@rmh.nthames.nhs.uk
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy* / Q000401:mortality; D015458:Leukemia, T-Cell / Q000188:drug therapy* / Q000401:mortality; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000401:mortality; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab